By Daniella Parra
Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up to $740 million.
Araris’ AraLinQ platform enhances ADC drug design, improving stability, safety, and anti-tumor effects, the company said. Its preclinical-stage ADC candidates for hematological and solid tumors are expected to enter clinical trials between 2025-2026.
“Araris’ unique ADC technology represents a quantum leap for the ADC field, potentially offering precise payload delivery of multiple mechanisms of action simultaneously to the tumor, with less toxicity,” Dragan Grabulovski, CEO and Co-founder of Araris said. “We are proud to combine with Taiho, our partner since November 2023, whose significant cancer expertise will support us in turbo-charging the clinical development of our potent ADC candidates in hematological and solid tumors.”
